Background. Total thyroidectomy (TT) with prophylactic central neck dissection (pCND) remains controversial for clinically nodal-negative (cN0) papillary thyroid carcinoma (PTC), and the issue of cost rarely has been examined. We evaluated whether pCND at the time of TT is more cost-saving than TT alone in the medium-to longterm. Methods. For a hypothetical group of 50-year-old females with a 1.5-cm cN0 PTC, a decision-tree model using TreeAge Software was developed to simulate outcomes and compare the 20-year accumulative direct cost between TT alone and TT?pCND strategies. Baseline values and ranges were determined from a systematic review of the literature. Sensitivity analyses were conducted to test model strength. Cost estimate of surgical procedures, complications, and radioiodine (RAI) ablation was based on government gazette. Results. The cost accrued per patient for the primary operation under TT alone and TT?pCND strategies were USD 6,702.81 and USD 10,062.35, respectively, whereas the cost for the reoperative procedure were USD 12,981.40 and USD 12,509.09, respectively. The 20-year accumulative cost for TT alone and TT?pCND strategies were USD 19,888.36 and USD 22,760.86, respectively. The incremental cost per patient was USD 2,872.50. In the univariate and bivariate sensitivity analyses, no change in conclusion was seen by varying the rates of complications, annualized locoregional recurrences and RAI, or by extending the model to 50 years. Conclusions. From a pure economic institution's perspective, TT?pCND is more expensive in the medium-and long-term and seems less justified compared with TT alone for cN0 PTC.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma with its incidence doubled during the past two decades. [1] [2] [3] [4] [5] However, despite good prognosis, locoregional recurrence (LRR) is common after curative surgery. 6 With recognition of the step-wise progression of metastasis from central (level VI) to lateral compartments (levels II-V), routine prophylactic central neck dissection (pCND) has been advocated at the time of total thyroidectomy (TT) to reduce LRR. [7] [8] [9] Although formal central neck dissection is indicated in clinically positive nodal disease, it remains controversial in clinically negative-nodal disease (cN0). 10 There is little evidence to suggest patients with cN0 PTC would benefit from pCND at the time of TT, although a recently meta-analysis has found a 35 % reduction in LRR over TT alone. 11 However, this was at the expense of higher risks of temporary hypoparathyroidism and overall morbidity. 11 Therefore, performing pCND may cause initial higher patient morbidity but may be beneficial in the medium-to long-term because of reduced LRR. 9, 11 Despite this ongoing debate of whether routine pCND should or should not be performed, the issue of cost rarely has been discussed and examined. In the era of cost containment and increasing healthcare costs, it is imperative that clinicians include dollar cost of a surgical intervention (such as pCND) as part of their decision making process. In the context of pCND for cN0 PTC, the question is whether the higher expected initial cost (due to greater extent of surgery, higher morbidity, and more frequent radioiodine (RAI) use) could be compensated in the medium-to longterm by the lower cost from reduced LRR and need for reoperation. [11] [12] [13] [14] [15] We used a decision-tree analysis model to compare the medium to long-term cost between the two strategies: TT alone, and TT?pCND in a reference population with biopsy-proven cN0 PTC.
MATERIALS AND METHODS

Case Definition
A hypothetical cohort of 100,000 nonpregnant female patients aged 50 years with an unifocal intrathyroidal 1.5-cm cN0 PTC in the right thyroid lobe and with no previous thyroidectomy or neck irradiation was simulated in the model.
The Model
A decision-tree model using TreeAge Software Pro version 2012 (Treeage Software, Inc., Williamstown, MA) was constructed to compare the estimated long-term cost between TT alone and TT?pCND. Patients were entered into the model after primary operation as the initial state, based on the Markov process with 1-year cycle as outlined in Fig. 1 . Patients underwent one of two strategies, namely TT alone or TT?pCND, and were followed until age 70 years. The model included three major health states after primary treatment and they were disease-free, surveillance with LRR, and death. In case of LRR involving either the central, lateral, or central and lateral compartments, a compartment-oriented reoperation followed by RAI were offered. Patient in either two strategies may suffer one of six surgical complications from the primary operation. Patients were followed up until stage of death or age 70 years.
Assumptions
It was assumed that all pCNDs were unilateral only and surgical resection was the only option in patients with LRR involving the central, lateral, or central and lateral compartments. All patients were assumed suitable and agreed for reoperation at the time of LRR. For simplicity, only a maximum of one LRR and one reoperation per patient was assumed. Similarly, only one surgical complication was encountered after primary operation and reoperation. Reoperative CND was assumed bilateral while reoperative lateral SND was assumed unilateral involving levels II-V.
An empirical 3 GBq RAI was given after each reoperation. The costs of preoperative assessment and surveillance were assumed the same in both groups. Full compliance was assumed for all kinds of assessment, treatment, and surveillance.
Probabilities
Estimates of the complications arising from the primary operation, postoperative RAI ablation, and central and/or lateral recurrences after primary operation were based a comprehensive literature search but were limited to those studies that directly compared surgical complications between TT alone and TT?pCND in cN0 PTC. Details of the search have been previously described. 11 Estimates of the complications arising from reoperation and death from nonthyroidal causes were based on separate PubMed literature searches. To come up with an estimate for all clinical parameters, base-case values were derived from multiple studies synthesized in literature search. We tested the possible range of the lowest and highest values from aforementioned studies in the sensitivity analysis. The annual mortality rate of female patients in quinquennial age groups (e.g., 50-54, 55-59 years, etc.) were obtained from the population projection in 2012. 16 
Cost Data
This model looked at the financial impact of two strategies from the institutional perspective. The cost from the institutional perspective only included the direct costs of the procedure, its associated complications, and hospitalization. Indirect costs, such as loss of productivity and wages, were not included. The unit cost of all surgical procedures, RAI, and complications were based on the Hospital Authority (HA) cost published in the 2013 Government Gazette. 17 The Gazette provides the official price list of all medical services utilized in healthcare sector. The operation costs included preoperative workup cost, fees for the surgeon, anesthetist and supporting staff, drugs related to the operation, operating room, consumables, and all other general expenses. Costs related to prolonged hospitalization or readmission due to complications or medical comorbidities were not included. Drug costs were retrieved from the drug price enquiry system. 18 Cost data evaluated in Hong Kong dollar (HKD) (year 2013 values) were converted to U.S. dollars (USD) at an exchange rate of USD 1.0 = HKD 7.8 and rounded off to the nearest whole USD. Therefore, all monetary values were expressed in USD for international comparisons.
Base-Case Analysis
The 20-year accumulative medical cost accrued per patient for two strategies was calculated. All the costs were discounted by an annual rate of 3 %, in line with the established guideline for cost-analysis. 19 The incremental cost difference was defined as the cost of TT?pCND minus the cost of TT alone. 
Sensitivity Analysis
Our models performed the one-way (univariate) sensitivity analysis to explore the uncertainty on the clinical parameters of complications, RAI ablation, and annualized recurrence rates. Each clinical parameter was varied over the lowest and highest possible values suggested in the literature search, whereas the value of other clinical parameters remained constant. Because the complication rates in primary operation differed, those complication rates from primary operation were assumed the same between the two strategies in bivariate sensitivity analysis. We also performed bivariate sensitivity analysis on the surgical complications in which we varied the relative differences in rate of permanent vocal cord palsy complication between TT?pCND and TT alone to obtain the incremental cost equivalence. Threshold analysis was undertaken to capture the threshold clinical values at which the costs of TT alone and TT?pCND became equivalent. We expanded considerably more on the range of threshold analysis by adopting the theoretical possible range from zero to one.
RESULTS
Base-Case Analysis
The base-case analysis was based on the previously stated assumptions and used the base-case probabilities and costs from Tables 1 and 2 . The costs accrued per patient in the primary operation under the TT alone and TT?pCND strategies were USD 6,702.81 and USD 10,062.35, respectively, and the costs accrued per patient in the reoperation under the TT alone and TT?pCND strategies were USD 12,981.40 and USD 12,509.09, respectively. Table 3 shows the results of base-case and sensitivity analyses. From the institutional perspective, the 20-year accumulative cost of TT alone accrued per patient was USD 19,888.36, whereas the cost of TT?pCND accrued per patient was USD 22,760.86. Therefore, TT alone was the less expensive than TT?pCND to the institution.
Sensitivity Analysis
The univariate sensitivity analysis was performed by varying key model parameters to verify the robustness of model conclusion. No change in the conclusion was seen by varying various key parameters, including rates of complications, annualized LRR, and RAI after primary operation. Even when the model was extended to 50 years, TT alone was less expensive than TT?pCND. In the bivariate sensitivity analysis, when the total morbidity after the primary operation in TT?pCND was assumed to be equal to TT alone, TT?pCND remained more costly than TT alone. When the total morbidity of TT?pCND was reduced from 29.96 to 14.94 % (i.e., total morbidity of TT alone), the incremental cost remained positive (USD 2,870.29). In fact, regardless of the actual total morbidity rate, as long as the two strategies had similar morbidity, TT?pCND remained more expensive than TT alone. Table 4 shows the threshold analysis. Of all the clinical key model parameters, only five parameters could have made the direct medical cost of TT alone CTT?pCND. These five parameters were permanent vocal cord palsy rate during TT alone, the three annualized recurrence rates under the TT alone strategy, and rate of RAI ablation after TT?pCND. For the first parameter, the rate of permanent vocal cord palsy during TT alone had to increase above 59.84 %, whereas the rate of permanent vocal cord palsy during TT?pCND remained at 1.22 % before TT alone could become more costly than TT?pCND. In that scenario, the total morbidity would have to become 73.76 % in TT alone while TT?pCND remained at 29.96 %. Increasing the rates of central, lateral, and central and lateral recurrence in TT alone also resulted in a decrease in incremental costs. The annualized central recurrence rate in TT alone had to increase from 0.63 to 7.34 % before TT alone became more expensive. Similarly, the annualized lateral and central and lateral recurrence rates in TT alone had to increase from 0.38 to 4.54 % and 0.56 to 3.71 %, respectively, before TT alone would become more costly than TT?pCND. A decrease in RAI ablation from 76.87 to 1.67 % in TT?pCND while maintaining the rate of RAI in TT alone at 53.44 % also resulted in equivalent direct medical costs between the two strategies.
DISCUSSION
To our knowledge, the issue of costs has rarely been discussed in the context of pCND. Our key question was whether adding pCND at the time of TT in cN0 PTC would be cost-saving in the medium-to long-term. Our initial hypothesis was that although the addition of pCND at the time of TT may accrue a higher initial cost, this extra cost may perhaps be recovered by the lower LRR and need for reoperation over time. [11] [12] [13] [14] Our hypothesis was supported by the fact that the primary operation cost accrued per patient in the TT alone was less than TT?pCND (USD 6,702.81 and USD 10,062.35, respectively), whereas the reoperation cost accrued per patient in TT alone was more than TT?pCND (USD 12,981.40 and USD 12,509.09, respectively). However, despite these findings, TT?pCND was USD 2872.50 more expensive than TT alone during a 20-year period. Even when the model was extended to a 50-year period, the TT?pCND remained more expensive by USD 2,737.52. The factors that led to the higher initial cost in TT?pCND included extra cost of pCND, higher complication rates from the primary operation, and higher frequency of RAI ablation after primary operation. Under our service cost structure, pCND cost USD 2,494.0 and that accounted for a third of the total cost of TT?pCND (USD 7,006) or [50 % the cost of TT (USD 4,512). Also because the overall initial complication rate was higher in TT?pCND than TT alone (29.96 vs. 14.94 %), the initial cost of TT?pCND was higher than TT alone. Regarding CND central neck dissection, RAI radioiodine ablation a Total morbidity was the sum of all complications; patients with more than one complication were counted as one RAI ablation, because patients who underwent pCND were more likely to be upstaged by metastatic central lymph nodes, [7] [8] [9] 11, 12 RAI ablation was given more frequently in the TT?pCND strategy.
Although the cost accrued per patient in the reoperation setting was higher in the TT alone strategy than TT?pCND strategy (i.e., consistent with our initial hypothesis), the actual cost difference over time was not enough to compensate for the initial cost difference. The incremental cost difference was only USD 472.31, whereas the incremental cost difference in the primary operation setting was USD 3,359.54. However, this could be explained firstly because under our service cost structure, the cost of primary CND and reoperative CND was similar, even though reoperation required greater surgical skills and longer procedural time. 13, 14 Secondly, from the literature, the complication rates from reoperation were not significantly higher than those from the primary operation. Both temporary hypoparathyroidism (20.64 vs. 17.14 %) and overall morbidity (29.96 vs. 30.4 %) rates were not too dissimilar to reoperative CND. The other factor was the low absolute LRR in TT alone. Although the LRR in TT alone was higher than that in TT?pCND (1.57 vs. 1.07 %), the absolute difference was small, which led to smaller incremental cost difference. In fact, based on the threshold analysis, the annualized LRR had to increase by more than 6-12 times before the cost of the two strategies become equivalent at 20 years. Other clinical scenarios were when the permanent vocal cord palsy rate in TT alone increased to C60 %, whereas the rate in TT?pCND remained 1.7 % or when the use of RAI ablation after TT?pCND was reduced from 76.87 to 1.67 %.
Despite these findings, there were several shortcomings with our model. First, our findings were based on our own unique service cost structure and so the actual costs may not be applicable to other health systems and countries. Second, despite a comprehensive literature search for estimating different probabilities, selection and publication biases could not be completely ruled out. For example, base-case temporary and permanent vocal cord palsy rates in TT?pCND were not significantly higher than the TT TT total thyroidectomy, pCND prophylactic central neck dissection TT total thyroidectomy, pCND prophylactic central neck dissection, SND selective neck dissection, LR locoregional, RAI radioiodine alone (3.28 vs. 3.1 % and 1.7 vs. 1.22 %, respectively). Nevertheless, according to the two-way sensitivity analysis, even if TT?pCND had the same overall morbidity as TT alone, TT alone remained the less costly strategy. Third, some of the assumptions might have been overly simplified. For example, assuming one LRR and one reoperation per patient would appear overly simplified, because up to 10 % of patients with first-time LRR would require more than one reoperation. 14, 15 Given the higher LRR rate in the TT alone, including two or more reoperations could potentially increase the cost accrued in TT alone. In addition, although the literature would suggest that RAI is given more often after TT?pCND than TT alone because of tumor upstaging, there is currently no evidence to suggest that it should. 11, 12 In fact, some would argue that if nodal status is unknown (such as those without pCND), RAI should be given routinely (i.e., more frequently) to facilitate long-term follow-up.
One point worth noting is that this study evaluated only the costs accrued from an institution's perspective and not from the surgeon's or patient's perspective. To the surgeon or patient, TT?pCND might still be more preferable, because overall LRR risk was reduced by almost half (from 1.57 to 0.87 %). Perhaps, future studies could also study the relative impact of primary operation and reoperation on patients' quality of life.
CONCLUSIONS
From an institution's perspective, the addition of pCND at the time of TT for cN0 PTC was not cost-saving in the medium-to long-term. This was partly because of higher initial cost in TT?pCND and relatively small difference in LRR between TT alone and TT?pCND. From an institution's perspective, TT alone was a much less costly strategy than TT?pCND.
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